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Background. HIV posttreatment controllers are rare individuals who start antiretroviral therapy (ART), but maintain HIV sup-
pression after treatment interruption. The frequency of posttreatment control and posttreatment interruption viral dynamics have 
not been well characterized.
Methods. Posttreatment controllers were identified from 14 studies and defined as individuals who underwent treatment inter-
ruption with viral loads ≤400 copies/mL at two-thirds or more of time points for ≥24 weeks. Viral load and CD4+ cell dynamics were 
compared between posttreatment controllers and noncontrollers.
Results. Of the 67 posttreatment controllers identified, 38 initiated ART during early HIV infection. Posttreatment controllers 
were more frequently identified in those treated during early versus chronic infection (13% vs 4%, P < .001). In posttreatment con-
trollers with weekly viral load monitoring, 45% had a peak posttreatment interruption viral load of ≥1000 copies/mL and 33% had a 
peak viral load ≥10 000 copies/mL. Of posttreatment controllers, 55% maintained HIV control for 2 years, with approximately 20% 
maintaining control for ≥5 years.
Conclusions. Posttreatment control was more commonly identified amongst early treated individuals, frequently characterized 
by early transient viral rebound and heterogeneous durability of HIV remission. These results may provide mechanistic insights and 
have implications for the design of trials aimed at achieving HIV remission.
Keywords. HIV; treatment interruption; posttreatment controller; HIV rebound; viral decay.
One of the highest priorities of the human immunodeficiency 
virus (HIV) field is the search for therapies that induce sus-
tained antiretroviral therapy (ART)-free HIV remission. While 
discontinuation of ART leads to rapid viral rebound in the vast 
majority of individuals [1], a small subset can maintain con-
trol of HIV replication and provide evidence that natural con-
trol of HIV replication after an initial course of ART is possible 
[2–4]. However, the study of these posttreatment controllers has 
been hindered by how few of these individuals have been iden-
tified to date. This is due to a combination of factors, including 
(1) in clinical practice, patients are strongly discouraged from
interrupting ART, (2) there are few trials involving a treatment 
interruption, and (3) within treatment interruption studies, the 
frequency of posttreatment control is low and their detection is 
hindered by early ART resumption.
Given the rarity of posttreatment controllers at a given clin-
ical center or trial, the true frequency of this phenomenon has 
been difficult to ascertain, especially given the significant het-
erogeneity in both the study populations and posttreatment 
controller definitions [2–11]. The most comprehensive evalu-
ation of posttreatment controllers to date has been the French 
VISCONTI cohort of 14 individuals [6], but this analysis was 
limited by the small size and the lack of participants treated 
during chronic HIV infection. In the Control of HIV after 
Antiretroviral Medication Pause (CHAMP) study, we report 
67 posttreatment controllers identified through 14 treatment 
interruption studies involving more than 700 participants. 
This represents the largest number of posttreatment controllers 
reported to date and the results provide an estimated posttreat-
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individuals, the range of posttreatment interruption viral load 
peaks, subsequent viral decay rates, and the durability of viral 
remission over time. As more clinical trials are conducted to 
test strategies for inducing post-ART HIV remission, treatment 
interruption will increasingly be employed to demonstrate their 
efficacy in delaying HIV rebound, reducing viral set points, and 
producing posttreatment controllers. Understanding the fre-
quency of posttreatment control and their posttreatment inter-
ruption viral dynamics may provide mechanistic insights and 
has implications for the design of trials aimed at achieving HIV 
remission.
METHODS
Study Design and Participants
The CHAMP study includes participants from 8 AIDS Clinical 
Trials Group (ACTG) studies (ACTG 371 [12], A5024 [13], 
A5068 [14], A5102 [15], A5130 [16], A5170 [17], A5187 [18], 
and A5197 [19]), the Montreal Primary HIV Infection Cohort 
(Montreal PIC) [20], the Seattle Primary Infection Program 
(SeaPIP) [21], the University of California San Diego Primary 
Infection Cohort (UCSD PIC) [7], a National Institutes of 
Health (NIH) therapeutic vaccine trial [9], the University of 
California San Francisco (UCSF) OPTIONS study [22], and 
the Ragon HIV Controllers cohort (Supplementary Figure  1) 
[23]. Posttreatment controllers were defined as individuals who 
remained off ART for ≥24 weeks posttreatment interruption 
and maintained viral loads ≤400 copies/mL for at least two-
thirds of the time points. Viral loads >400 HIV-1 RNA copies/
mL were acceptable if the participant was subsequently able to 
suppress to ≤400 HIV-1 RNA copies/mL and maintained viro-
logic control through week 24 posttreatment interruption. Early 
treated posttreatment controllers were identified from the fol-
lowing studies: ACTG 371, A5187, SeaPIP, Montreal PIC, UCSF 
OPTIONS, and the NIH study (Supplementary Table 1) [9, 12, 
18, 21, 22, 24]. The posttreatment controller frequency for early 
treated participants was calculated for the 148 participants of 
ACTG 371, A5187, SeaPIP, and the NIH study. Posttreatment 
controller frequency for participants who initiated ART during 
chronic HIV infection was calculated for the 460 participants of 
A5024, A5068, A5102, A5130, A5170, and A5197. Additional 
details on the study cohorts and calculation of posttreatment 
controller frequency can be found in the Supplementary 
Methods.
Data and Statistical Analyses
Viral load and CD4+ cell dynamics were compared between 
posttreatment controllers and noncontrollers. Noncontrollers 
were ACTG participants who did not receive any immuno-
logic interventions (eg, therapeutic vaccines), were virologically 
suppressed at the time of treatment interruption, and did not 
meet the posttreatment controller criteria after treatment inter-
ruption. The CD4+ cell decline analysis was performed for all 
participants who had ≥3 CD4+ count determinations during the 
first 24 weeks posttreatment interruption, at least 1 of which 
must be within 4 weeks of week 24. CD4+ cell slope was cal-
culated with a linear regression equation. Early viral load peak 
was defined as the highest documented viral load during the 
first 24 weeks posttreatment interruption. Posttreatment con-
trollers with viral load data 1 week prior to and after the viral 
load peak were defined as having weekly measurements. Viral 
decay rates for posttreatment controllers with an early viral load 
peak ≥1000 HIV-1 RNA copies/mL were calculated with the 
following formula: (Ln [peak viral load] − Ln [subsequent viral 
load]) / days in between. Viral decay rates for the posttreatment 
controllers were compared to the decay rates of 3 comparison 
groups: (1) noncontrollers from the ACTG treatment interrup-
tion studies; (2) untreated acutely infected participants from a 
published viral dynamics analysis [25] and from the UCSD PIC 
[26]; and (3) the phase 1 and 2 viral decay rates of individuals 
from 2 ACTG studies (A5160s and A5166s) initiating first-line 
nonnucleoside reverse transcriptase inhibitor (NNRTI)-based 
ART [27, 28]. Viral decay rate analysis for the posttreatment 
controllers, noncontrollers, and untreated acutely infected par-
ticipants was limited to participants with available viral load 
within 1–2 weeks of the viral load peak to match the duration 
of first-phase viral decay found in NNRTI-treated individuals.
At each year posttreatment interruption, the point estimates 
of the proportion of posttreatment controllers who maintained 
viral control was calculated as follows: (N with viral control) / 
(N with viral control + N with documented loss of viral control 
before that time point). In the later years, a smaller number of 
participants had available viral load data and the uncertainty 
around the point estimates is depicted by an upper and lower 
bound. The upper bound is calculated by assuming that all par-
ticipants who did not have viral load data through that time 
point continued to suppress HIV and the lower bound assumed 
that they had all lost viral control.
Wilcoxon-Rank sum tests were used for comparing contin-
uous data and Fisher exact test was used to compare the post-
treatment controller frequency of those initiating ART during 
early versus chronic infection.
RESULTS
A total of 67 posttreatment controllers were identified from 
the 14 studies enrolling over 700 participants, including 38 
who were treated during early HIV infection and 25 who were 
treated during chronic infection (Supplementary Figure  2). 
Four individuals from the Ragon Controller studies with early 
ART initiation but incomplete laboratory records were catego-
rized as having an “ambiguous” timing of ART initiation. There 
were no significant differences in the characteristics of those 
treated during early versus chronic infection with the exception 
that early treated individuals were more likely to receive a prote-
ase inhibitor-based regimen and received a shorter duration of 
ART prior to the treatment interruption (Table 1). The median 
duration of documented viral suppression after ART discon-
tinuation was 89 weeks (Q1, Q3: 44, 174 weeks). Posttreatment 
controllers were more commonly identified in those treated 
during early versus chronic infection (13% vs 4%, P  <  .001). 
Including early treated participants from the UCSF OPTIONS 
and UCSD PIC cohorts, the lower and upper bounds of post-
treatment controller frequency was 11% and 14%, respectively. 
Incorporating the chronic-treated participants from the UCSF 
OPTIONS study had no effect on the posttreatment controller 
estimate. Posttreatment controllers treated during early infec-
tion had slightly lower pre-ART viral load than noncontrollers 
(posttreatment controllers vs noncontrollers: 4.7 vs 4.9 log10 
HIV-1 RNA copies/mL, P = .09).
We evaluated CD4+ cell decline over the first 24 weeks of the 
treatment interruption. The median CD4+ cell counts prior to 
treatment interruption was 882 cells/mm3 for posttreatment 
controllers and 825 cells/mm3 for noncontrollers (P = .7). In the 
first 24 weeks after ART discontinuation, CD4+ levels were gen-
erally preserved in the posttreatment controllers, but declined 
in the noncontrollers (posttreatment controllers vs noncontrol-
lers: −32 vs −221 CD4+ cells/mm3, P <  .001; Figure 1). These 
findings were mirrored both in the early and chronic-treated 
participants.
After the treatment interruption, a subset of posttreatment 
controllers had transient viral rebound in the first 24 weeks 
of treatment interruption before regaining viral control. The 
median viral load peak was lower for posttreatment control-
lers than noncontrollers (posttreatment controllers vs noncon-
trollers: median 2.6 log10 HIV-1 RNA copies/mL vs 4.7 log10 
HIV-1 RNA copies/mL, P  <  .001; Figure  2A). This difference 
was consistent for individuals treated during early or chronic 
infection. In participants with detectable viral loads, no signifi-
cant difference was measured for the time to peak viral load for 
posttreatment controllers versus noncontrollers (9 vs 8 weeks 
posttreatment interruption; Figure  2B). Amongst all post-
treatment controllers, approximately 90% had a peak viremia 
<10 000 HIV-1 RNA copies/mL and 70% had peak viral loads 
<1000 HIV-1 RNA copies/mL (Figure 3A). In contrast, 98% of 
noncontrollers had a peak viremia ≥1000 HIV-1 RNA copies/
mL and 80% had a peak viral load ≥10 000 HIV-1 RNA cop-
ies/mL (Figure 3B). As there were differences in the follow-up 
schedule among clinical studies, we evaluated the effect of viral 
load testing frequency on the magnitude of the viral load peaks. 
We compared the documented viral load peaks in participants 
who were undergoing weekly viral load monitoring (n = 9) com-
pared to those with less frequent viral load monitoring (n = 52). 
Higher viral load peaks were more commonly observed in 
those with more frequent (ie, weekly) viral load monitoring. 
For instance, a greater proportion of posttreatment controllers 
with weekly measurements had viral load peaks ≥10 000 HIV-1 
RNA copies/mL versus those with less frequent viral load 








Median age at treatment interruption, y (Q1, Q3) 41 (35,47) 38 (33,46) 42 (39,49) .12
Sex, %
 Male 81 84 76 .52
 Female 19 16 24
Race, %
 Black 25 16 40 .08
 White 69 79 52
 Hispanic 4 3 8
More than 1 race 1 3 0
Median duration of ART, weeks (Q1, Q3) 195 (60,330) 121 (53,242) 289 (207,331) <.001
Combination therapy regimen, %
 NNRTI 34 16 54 .01
 PI 58 70 46
 INSTI 3 5 0
 Multiple 5 8 0
Study, %
AIDS Clinical Trials Group 46 32 76
Montreal Primary HIV Infection Cohort 9 16 0
Seattle Primary Infection Program 4 8 0
Ragon HIV Controllers Cohort 22 13 24
UCSF Options Cohort 12 21 0
 NIH 6 11 0
Four individuals have unclear timing of ART and thus are not included in either the early or chronic-treated groups. 
Abbreviations: ART, antiretroviral therapy; INSTI, integrase strand-transfer inhibitor; NIH, National Institutes of Health; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease 
inhibitor; Q, quartile; UCSF, University of California San Francisco. 
testing (33% vs 8%, P = .06; Figure 3C). When viral loads were 
measured on a weekly basis, 45% of the posttreatment control-
lers had viral load peaks ≥1000 HIV-1 RNA copies/mL versus 
31% amongst posttreatment controllers with less frequent viral 
load sampling, although this comparison was not statistically 
significant. A similar trend of higher viral load peaks was also 
observed for the noncontrollers with more frequent posttreat-
ment interruption viral load monitoring (Figure 3C).
For posttreatment controllers with a viral load peak ≥1000 
HIV-1 RNA copies/mL and subsequent viral load measure-
ment 1–2 weeks later (Supplementary Figure 3), we calculated 
the rate of viral decay and compared it to the rates for 3 dif-
ferent groups: (1) noncontrollers after treatment interruption, 
(2) untreated viral decay rates during acute infection, and (3)
phase 1 and 2 decay rates after ART initiation. Phase 1 viral load 
decay represents a steep decline in viral load during the first 2
weeks of ART while phase 2 decay reflects a slower subsequent
viral load decrease [27, 28]. Overall, posttreatment controllers
had a median decrease of 1.2 log10 HIV-1 RNA copies/mL over 
the subsequent 1–2 weeks. The ART-free viral decay of post-
treatment controllers was found to be 0.23 per day, similar to 
the viral decay observed during untreated acute infection [25, 
26] and significantly faster than that seen in the noncontrollers
after treatment interruption (posttreatment controllers vs non-
controllers: 0.23 vs 0.11, P <  .01; Figure 4). The viral decay in 
posttreatment controllers was also compared to that of NNRTI-
based ART-naive individuals initiating an NNRTI-based regi-
men [27, 28]. Posttreatment controllers had a slower viral decay 
compared to the phase 1 decay after ART initiation (0.23 vs 
0.66, P < .001) and faster than phase 2 decay after ART initiation 


































































































































































Figure 2. Highest viral load in posttreatment controllers (PTCs) versus noncontrollers (NCs) over the first 24 weeks of treatment interruption. A, Early viral load peak levels 
in PTCs versus NCs, also categorized by timing of ART initiation. B, The week of treatment interruption at which an early detectable viral load peak occurred. Boxes depict 
median and interquartile range; whiskers show the 5th and 95th percentile. Dots represent all data not contained within the whiskers. PTCs with ambiguous timing of ART 
start were excluded from the analysis that categorized PTCs by early versus chronic ART initiation (3 and 1 participants for A and B, respectively).
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Figure 1. Changes in CD4+ cells in the initial 24 weeks of treatment interruption in 
posttreatment controllers (PTCs) versus noncontrollers (NCs). Boxes depict median and 
interquartile range; whiskers show the 5th and 95th percentile. Dots represent all data not 
contained within the whiskers. The open blue circle depicts a value of −2163 cells/mm3.
We also assessed the durability of posttreatment control in 
the first 5  years after treatment interruption. The proportion 
of posttreatment controllers who remained virologically sup-
pressed in years 1–5 were 75%, 55%, 41%, 30%, and 22%, respec-
tively (Figure 5). Of note, there was a high degree of uncertainty 
in the point estimates for durability of viral control in the later 
years due to an increasingly limited number of participants with 
available viral load data. There were no significant differences in 
the durability of posttreatment control between posttreatment 
controllers when categorized by the timing of ART initiation or 
by pretreatment interruption ART drug class (Supplementary 
Figure 4). Two posttreatment controllers, both treated during 
early infection, maintained documented viral control for more 
than 10 years after treatment interruption. One of these post-
treatment controllers had a pre-ART viral load of 196 000 cop-
ies/mL and initiated ART 5 weeks after diagnosis of infection. 
Pre-ART viral loads were not available for the other posttreat-
ment controller.
Amongst ACTG trial participants, 8 of the 19 (42%) chron-
ically treated posttreatment controllers were identified from 
the A5068 study. The frequency of posttreatment control was 
10% in A5068 versus 3% for all other ACTG studies enrolling 
chronic-treated participants (P = .01; Supplementary Figure 5A). 
A5068 was a 4-arm study evaluating the impact of an ALVAC-
HIV vCP1452 therapeutic vaccine  with or without  multiple 
structured treatment interruptions [14]. The structured treat-
ment interruptions involved 2 short treatment interruptions 
lasting 4–6 weeks, each followed by 16 weeks of ART, and a final 
longer period of treatment interruption. In A5068, the major-
ity of posttreatment controllers (6 out of 8) were identified in 
the 2 study arms that included the structured treatment inter-
ruptions. Of those who underwent structured treatment inter-
ruptions, 15% eventually became posttreatment controllers as 
compared to only 5% of A5068 participants who underwent a 
single treatment interruption (Supplementary Figure 5B).
DISCUSSION
The presence of individuals who can maintain HIV suppres-
sion after discontinuing ART provides hope that the goal of 
sustained HIV remission is possible. However, as few patients 
undergo intensively monitored treatment discontinuations, 
the frequency of this phenomenon has been challenging to 
quantify. In published studies to date, a wide range of post-















































































Figure 3. Early viral load peaks during the first 24 weeks of treatment interruption. Proportion of posttreatment controllers (PTCs) (A) and posttreatment noncontrollers 
(NCs) (B) categorized by viral load peak. C, Proportion of viral load peaks in the PTCs and NCs for participants with weekly versus less frequent viral load measurements. P 
value represents Fishers exact test of PTCs with viral load peak ≥10 000 HIV-1 RNA copies/mL with weekly viral load measurement versus less frequent monitoring. For NCs, 
the comparison is for the proportion with viral load peak ≥100 000 HIV-1 RNA copies/mL. Abbreviation: Cp/mL, HIV-1 RNA copies/mL.
from 0% to 26% of those undergoing treatment interruption 
[2–9]. These differences are likely influenced by factors such 
as small study sizes and heterogeneity, both in the timing of 
ART initiation and the precise posttreatment controller defi-
nitions. In addition, almost all of the previously reported 
posttreatment controllers have been individuals who initiated 
ART during acute/early infection [3, 4, 6, 9]. Posttreatment 
control in individuals treated during chronic infection has 
rarely been reported [8, 29] and this phenotype has not been 
well characterized. We performed a pooled analysis of over 
700 participants of treatment interruption studies and found 
that 13% of those treated during early infection met our 
posttreatment controller definition, which was significantly 
higher than the 4% frequency of chronic-treated posttreat-
ment controllers. This finding represents another benefit of 
early ART initiation and suggests that patients treated during 
early HIV infection may have a lower barrier to achieving 
HIV remission and may be a priority for clinical studies of 
HIV eradication strategies.
Prolonged ART interruptions in noncontrollers were asso-
ciated with clinical events in the SMART study [30], but the 
extent of increased risk for posttreatment controllers is unclear. 
In ART-naive spontaneous controllers, CD4+ cell loss and clin-
ical disease progression are frequently observed [31]. We found 
that posttreatment controllers maintained a stable CD4+ cell 
count over the first 24 weeks of treatment interruption, unlike 
noncontrollers, who lost a median of 221 CD4+ cells. Additional 
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Figure 5. Durability of viral control. The solid line depicts the point estimates for the 
proportion of posttreatment controllers (PTCs) who maintained viral control at each time 
point. In the numbers under the X axis, the numerator represents PTCs who maintained 
viral control and the denominator are all PTCs with available data through this time point or 
were known to have lost viral control prior to this time point. Uncertainty around the point 
estimates is depicted by an upper and lower bound (dotted lines). For each time point, the 
upper bound is calculated by assuming that all participants who did not have virologic data 

































































Figure 4. Rate of viral load decay in posttreatment controllers (PTCs) versus 3 comparator groups. Viral decay rates per day were compared between PTCs versus 3 compar-
ator groups: (1) posttreatment noncontrollers (NCs) after treatment interruption, (2) antiretroviral therapy (ART)-naive participants during natural acute infection, and (3) phase 
1 and 2 decay rates in participants initiating first-line nonnucleoside reverse transcriptase inhibitor-based ART from 2 previously published ACTG trials [27, 28].
whether this portends future morbidity given the increased 
immune activation observed in spontaneous controllers [32].
The evaluation of new therapies to achieve an ART-free 
remission of HIV infection will require demonstration of effi-
cacy through ART interruption studies. However, these trials 
entail some potential risks, including possible clinical symp-
toms (eg, acute retroviral syndrome), immune damage, selec-
tion of HIV drug resistance, and HIV transmission to partners 
[33]. To prevent exposure of participants to extended periods 
of elevated viremia, modern treatment interruption trials often 
use the time to viral rebound as the primary outcome and ART 
is restarted once the viral rebound threshold has been reached. 
However, the optimal design of these studies is controversial, 
especially the viral load threshold at which participants would 
restart ART. A lower viral load threshold for reinitiating ART 
minimizes participant risk while a higher viral rebound thresh-
old may allow more time for a robust HIV-specific immune 
response to be mounted and may identify more instances of 
posttreatment control. In this analysis, we show that the viral 
load threshold at which participants of treatment interruption 
trials restart ART may have a dramatic effect on the frequency 
of posttreatment controller identification as many posttreat-
ment controllers demonstrate a transient elevated viremia prior 
to subsequent sustained virologic control. With weekly viral 
load monitoring, treatment interruption trials that restart ART 
at the 1000 HIV-1 RNA copy/mL threshold will miss almost half 
of the posttreatment controllers, while trials that use a 10 000 
HIV-1 RNA copy/mL threshold will miss a third of posttreat-
ment controllers. These results may be helpful to guide inves-
tigators as they weigh the risks and benefits of different study 
designs for future treatment interruption studies.
While nearly half of posttreatment controllers demon-
strated viral load peaks above 1000 HIV-1 RNA copies/mL, we 
observed a relatively rapid subsequent decline in viremia with 
a median decrease of 1.2 log10 HIV-1 RNA copies/mL over the 
subsequent 2 weeks. The rate of viral decay in these individu-
als was compared to the HIV decay rate after peak viremia in 
noncontrollers, individuals during untreated acute infection, 
and those initiating first-line NNRTI-based ART. We found 
that the viral decay rate in posttreatment controllers was signifi-
cantly faster than that of noncontrollers and similar to the viral 
decay rate observed after peak viremia in untreated acute HIV 
infection. Compared to individuals initiating first-line NNRTI-
based ART, the viral decay rate of posttreatment controllers was 
slower than phase 1 decay rates, but faster than phase 2 decay 
rates. During untreated acute HIV infection, the decline in 
viral load after peak viremia coincides with the development 
of HIV-specific cell-mediated immunity [34]. The differences 
in viral decay between posttreatment controllers and noncon-
trollers after treatment interruption may reflect a more robust 
cell-mediated immune response in the posttreatment control-
lers, although the rate of viral decay is also likely influenced by 
other factors, including viral fitness, availability of target cells, 
humoral immunity, and other host antiviral responses.
The results also show that posttreatment control is not always 
durable, with approximately half of individuals maintaining 
viral control at 2  years posttreatment interruption and 1 in 5 
posttreatment controllers able to sustain HIV remission for at 
least 5  years posttreatment interruption. However, there was 
substantial uncertainty in the point estimates for durability of 
viral control given the increasingly limited number of partic-
ipants with available data over time. This was primarily due 
to variability in the follow-up period for the various studies. 
These results show that routine longitudinal monitoring for 
HIV rebound is indicated for the posttreatment controllers. 
Additional studies are needed to also assess the mechanisms of 
HIV suppression in posttreatment controllers and the causes of 
eventual virologic failure.
Interestingly, we noted that the frequencies of posttreatment 
control were not uniform across studies, especially amongst 
those enrolling participants treated in chronic infection. 
Specifically, we found that a greater percentage of A5068 par-
ticipants were found to be posttreatment controllers. In A5068, 
participants were randomized to receive continued ART, two 4 
to 6-week cycles of structured treatment interruptions, ALVAC-
HIV vCP1452 therapeutic vaccine, or therapeutic vaccine 
plus structured treatment interruptions [14]. All participants 
underwent a subsequent prolonged treatment interruption. The 
increased frequency of posttreatment control was especially 
evident in those participants who were randomized to the study 
arms that included the sequential structured treatment inter-
ruptions, where the rates of posttreatment control rivaled that 
of participants treated during early infection. To date, there has 
not been a therapeutic vaccine strategy that has been shown 
to effectively induce sustained HIV remission. The “autovac-
cination” hypothesis proposes that viral reactivation during 
structured treatment interruptions may stimulate effective 
HIV-specific responses to the individual’s viral antigens. This 
approach has yielded more limited success in other studies with 
varying structured treatment interruption protocols and study 
populations [35, 36], but should be explored further as a poten-
tial strategy for achieving HIV remission.
This study has several limitations. First, we did not have 
pre-ART viral loads for all participants, especially those who 
were treated during chronic infection and we cannot rule out 
the presence of spontaneous HIV controllers. Second, the fre-
quency of posttreatment control is highly dependent on the 
posttreatment controller definition, including the viral rebound 
threshold and minimum duration of control. For instance, if the 
definition of posttreatment control was modified to include only 
participants who maintained viral suppression for ≥90% of the 
posttreatment interruption time points, the frequency of post-
treatment control would be reduced to 8% of early treated and 
2% of chronic-treated participants. We included posttreatment 
controllers who maintained viral remission for at least 24 weeks, 
which is a shorter time frame than some other studies [6]. This 
criterion excluded the vast majority of participants of treatment 
interruption trials as median to viral rebound is approximately 
3–4 weeks [1]. Importantly, this definition also allowed us to 
take a broader view of the spectrum of posttreatment control 
and to assess the durability of posttreatment control over time, 
an important characteristic that could not be studied in the 
timeframe of previous trials.
This paper represents a major collaborative effort in the field 
and for the first time provides the estimated frequency of post-
treatment control in both early and chronic-treated individuals, 
viral rebound dynamics after treatment interruption, and the 
rate of loss of viral remission over time. Our understanding of 
how posttreatment controllers achieve sustained HIV remission 
remains incomplete. A concerted international effort is needed 
to identify posttreatment controllers and to study the determi-
nants of posttreatment HIV control.
Supplementary Data
Supplementary materials are available at The Journal of 
Infectious Diseases online. Consisting of data provided by 
the authors to benefit the reader, the posted materials are not 
copyedited and are the sole responsibility of the authors, so 
questions or comments should be addressed to the corre-
sponding author.
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